Taiho has reupped its commitment to the second fund of Remiges, which focuses on spinouts of Japanese universities.

Remiges Ventures, a US-based venture capital firm focused on pharmaceutical technologies and medical devices developed by Japanese universities, has closed its second fund at $95m.
Limited partners include pharmaceutical groups EA Pharma, Senju Pharmaceutical and Taiho Pharmaceutical, as well as healthcare-focused investment firm 1Globe Capital.
Taiho committed up to $30m for the fund in 2019. It provided the same amount for Remiges’ first vehicle five years earlier, investing alongside peer Sumitomo Dainippon Pharma, and the fund subsequently closed…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
email
Linked in